We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment Efficacy for Drug Abuse and AIDS Prevention - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000210
First Posted: September 21, 1999
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Mclean Hospital
Information provided by (Responsible Party):
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders Heroin Dependence Drug: Buprenorphine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment Efficacy for Drug Abuse and AIDS Prevention

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
Study Start Date: September 1989
Study Completion Date: February 1996
Primary Completion Date: February 1996 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   26 Years to 41 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000210


Locations
United States, Massachusetts
McLean Hospital, Dept. of Psychiatry
Belmont, Massachusetts, United States, 2178
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Mclean Hospital
Investigators
Principal Investigator: Jack Mendelson, M.D. Mclean Hospital
  More Information

Responsible Party: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000210     History of Changes
Other Study ID Numbers: NIDA-06116-1
R18-06116-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: January 12, 2017
Last Verified: December 2002

Keywords provided by National Institute on Drug Abuse (NIDA):
opioid addiction
cocaine addiction

Additional relevant MeSH terms:
Substance-Related Disorders
Cocaine-Related Disorders
Heroin Dependence
Chemically-Induced Disorders
Mental Disorders
Opioid-Related Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists